Want to see PODD full AI Analyst Report?
Top Page
Insulet
(NASDAQ:PODD)
Select Model
Select Model
Rating:72Outperform
Price Target:
$165.00
▼(-19.01% Downside)
Action:Upgraded
Date:06/25/26
PODD scores well on financial performance (strong growth, improved profitability, and materially better cash generation/leverage) and is supported by a constructive earnings call with raised guidance. The overall score is held back by weak technical trend signals (below key moving averages with negative MACD), premium valuation (P/E ~34.5 with no dividend support), and product correction-related corporate-event risk.
Positive Factors
Revenue Scale & Margins
Insulet’s durable revenue scale and consistently high gross margins reflect a repeat-consumables business (pods) with strong unit economics. Large recurring demand and >60% gross margins create steady cash conversion potential, support R&D and manufacturing investment, and protect long-term profitability versus peers.
Negative Factors
Medical Device Corrections & Regulatory Scrutiny
Large-scale product corrections create persistent reputational and regulatory risk; replacements and remediation raise costs and invite closer scrutiny from regulators and payers. Even with provisioned costs, such events can slow adoption, complicate reimbursement and increase compliance/headcount needs over multiple quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Scale & Margins
Insulet’s durable revenue scale and consistently high gross margins reflect a repeat-consumables business (pods) with strong unit economics. Large recurring demand and >60% gross margins create steady cash conversion potential, support R&D and manufacturing investment, and protect long-term profitability versus peers.
Read all positive factors
Insulet Key Performance Indicators (KPIs)
Any
Revenue by Segment
Provides insight into which business segments are driving sales, highlighting areas of strength and potential growth within the company's operations.
Provides insight into which business segments are driving sales, highlighting areas of strength and potential growth within the company's operations.
Data provided by:
The Fly
The FlyInsulet (PODD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$10.55B
Dividend YieldN/A
Average Volume (3M)1.61M
Price to Earnings (P/E)35.5
Beta (1Y)0.46
Revenue Growth31.93%
EPS Growth-24.86%
CountryUS
Employees5,400
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)4.31
Shares Outstanding69,264,670
10 Day Avg. Volume1,605,881
30 Day Avg. Volume1,608,463
Financial Highlights & Ratios
PEG Ratio-1.97
Price to Book (P/B)13.20
Price to Sales (P/S)7.38
P/FCF Ratio52.94
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue3.59
Enterprise Value/Gross Profit5.05
Enterprise Value/Ebitda18.10
Forecast
1Y Price Target
$229.35Price Target Upside12.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
EPS Forecast (FY)6.48
Revenue Forecast (FY)$3.33B
Insulet Business Overview & Revenue Model
Company Description
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin...
How the Company Makes Money
Insulet primarily makes money by selling its Omnipod insulin delivery system through a recurring-consumables model. The main revenue stream is ongoing sales of disposable Omnipod pods (the wearable devices that deliver insulin and are replaced reg...
Insulet Earnings Call Summary
Earnings Call Date:May 06, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 05, 2026
Earnings Call Sentiment Positive
The call conveyed strong operational and financial momentum: robust revenue growth (30% constant-currency company; 45% international), margin expansion, ~40% EPS growth, raised full-year guidance, product R&D progress (Libre 3 Plus integration, Omnipod 6, fully closed-loop type 2) and healthy cash generation and buybacks. Offsetting items were largely identifiable, management-described headwinds and investments — including a voluntary medical device correction with related costs (~$12M), excess & obsolescence charges during a product transition (impacting gross margin >150 bps), short-term seasonality affecting Q1 U.S. new customer starts, modest retention pressure as type 2 mix grows, and elevated interest/cost pressures. Overall, positives (strong growth, margin expansion, product pipeline, guidance raise and cash actions) materially outweigh the disclosed challenges, which management framed as manageable, partly one-time, or investments to support durable growth.Positive Updates
Strong Top-Line Growth
Q1 total revenues of $762M, up 34% reported and 30% constant currency year-over-year; total Omnipod revenue grew ~33% on a constant currency basis. U.S. Omnipod revenue grew 28% in Q1 (approximately 26% underlying after a ~$10M timing benefit). International Omnipod revenue grew 59% reported and 45% constant currency.
Negative Updates
One-Time and Transitionary Margin Headwinds
Adjusted gross margin declined 90 basis points YoY to 71%; incurred ~ $12M of GAAP costs related to a March voluntary medical device correction. Excess & obsolescence costs tied to transition to new pod configurations negatively impacted adjusted gross margin by more than 150 basis points.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong Top-Line Growth
Q1 total revenues of $762M, up 34% reported and 30% constant currency year-over-year; total Omnipod revenue grew ~33% on a constant currency basis. U.S. Omnipod revenue grew 28% in Q1 (approximately 26% underlying after a ~$10M timing benefit). International Omnipod revenue grew 59% reported and 45% constant currency.
Read all positive updates
Company Guidance
Insulet guided Q2 Omnipod revenue growth of 21–23% and total company revenue growth of 20–22% (Q2 U.S. Omnipod 18–20%—including a ~$10M revenue shift into Q1 that creates ~200 bps headwind to Q2—and Q2 international Omnipod 28–30%), with foreign currency expected to provide roughly a 100 bp benefit to company growth in Q2 and ~200 bp benefit to international growth; for full‑year 2026 they raised targets to Omnipod revenue growth of 22–24% and total company revenue growth of 21–23% (full‑year U.S. Omnipod 20–22%; international Omnipod 26–28% with a reported ~300 bp FX tailwind and ~100 bp FX benefit assumed for the full year), plus about 100 bps of operating margin expansion, net interest expense of ~ $40M (≈+$15M year-over-year), a non‑GAAP tax rate of 21–22%, adjusted EPS growth of greater than 25%, and free cash flow roughly flat to 2025 while capex ramps to support manufacturing expansion.Insulet Financial Statement Overview
Summary
Income Statement
83
Very Positive
Balance Sheet
78
Positive
Cash Flow
81
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.90B | 2.71B | 2.07B | 1.70B | 1.31B | 1.10B |
| Gross Profit | 2.06B | 1.94B | 1.45B | 1.16B | 805.60M | 752.10M |
| EBITDA | 575.00M | 532.30M | 423.70M | 323.60M | 109.00M | 139.60M |
| Net Income | 302.80M | 247.10M | 418.30M | 206.30M | 4.60M | 16.80M |
Balance Sheet | ||||||
| Total Assets | 2.99B | 3.19B | 3.09B | 2.59B | 2.25B | 2.05B |
| Cash, Cash Equivalents and Short-Term Investments | 480.40M | 716.10M | 953.40M | 704.20M | 674.70M | 791.60M |
| Total Debt | 948.10M | 1.05B | 1.42B | 1.45B | 1.43B | 1.29B |
| Total Liabilities | 1.68B | 1.68B | 1.88B | 1.86B | 1.77B | 1.49B |
| Stockholders Equity | 1.30B | 1.52B | 1.21B | 732.70M | 476.40M | 556.30M |
Cash Flow | ||||||
| Free Cash Flow | 412.20M | 377.70M | 305.40M | 70.10M | -38.30M | -190.80M |
| Operating Cash Flow | 619.30M | 569.30M | 430.30M | 145.70M | 119.00M | -68.10M |
| Investing Cash Flow | -234.70M | -222.70M | -146.20M | -119.40M | -191.10M | -82.70M |
| Financing Cash Flow | -1.19B | -595.30M | -28.10M | -13.60M | -40.30M | 40.70M |
Insulet Technical Analysis
Negative
203.73
Price Trends
158.10
Negative
193.19
Negative
249.61
Negative
Market Momentum
-2.50
Negative
55.64
Neutral
89.56
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PODD, the sentiment is Negative. The current price of 203.73 is above the 20-day moving average (MA) of 149.25, above the 50-day MA of 158.10, and below the 200-day MA of 249.61, indicating a neutral trend. The MACD of -2.50 indicates Negative momentum. The RSI at 55.64 is Neutral, neither overbought nor oversold. The STOCH value of 89.56 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PODD.
Insulet Risk Analysis
Insulet disclosed 36 risk factors in its most recent earnings report. Insulet reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Insulet Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $25.99B | 28.34 | 33.83% | ― | 16.15% | 76.15% | |
75 Outperform | $20.52B | 26.48 | 11.05% | 0.94% | 8.73% | 26.55% | |
73 Outperform | $16.66B | 22.07 | 6.01% | 1.05% | 9.23% | -14.66% | |
72 Outperform | $10.55B | 35.47 | 21.38% | ― | 31.93% | -24.86% | |
62 Neutral | $26.34B | 23.29 | 8.96% | 3.30% | ― | ― | |
53 Neutral | $1.03B | -10.82 | -68.29% | ― | 4.54% | 49.66% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
PODD
Insulet
152.25
-149.37
-49.52%
DXCM
Dexcom
67.35
-16.23
-19.42%
PHG
Koninklijke Philips
27.19
3.45
14.54%
STE
Steris
210.57
-25.18
-10.68%
ZBH
Zimmer Biomet Holdings
86.09
-6.44
-6.96%
TNDM
Tandem Diabetes Care
15.09
-1.99
-11.65%
Insulet Corporate Events
Business Operations and StrategyExecutive/Board Changes
Insulet Appoints Jay Mazelsky to Board of Directors
Positive
Jun 25, 2026
On June 24, 2026, Insulet’s board appointed Jonathan “Jay” Mazelsky as a Class II independent director, effective July 1, 2026, with plans for him to stand for election at the 2027 annual shareholders’ meeting. As a non-emp...
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
Insulet Issues Voluntary Correction for Defective Omnipod Pods
Negative
May 26, 2026
On May 26, 2026, Insulet announced a voluntary medical device correction for specific lots of Omnipod 5, Omnipod DASH and Omnipod Eros Pods in the U.S. and certain international markets after product monitoring uncovered a manufacturing defect tha...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings
Insulet Shareholders Approve Proposals at Annual Meeting
Positive
May 21, 2026
On May 20, 2026, Insulet Corporation’s board approved amended and restated bylaws that designate the Delaware Court of Chancery, or other specified Delaware courts, as the exclusive forum for certain corporate and fiduciary duty claims, whil...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Insulet Clarifies FDA Injury Reports on Device Correction
Negative
Apr 29, 2026
On March 12, 2026, Insulet disclosed a voluntary medical device correction after receiving 18 reports of Serious Adverse Events linked to its product. On April 10, 2026, the company updated customers, adding 13 expired lots to the affected product...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.